RevBio Receives a $2.2 Million Phase II NIH Grant to Further Develop the Minimally Invasive Use of TETRANITE® to Treat Complex Spine Fractures By Michigan • Pittsburgh • Wyss|2025-10-09T13:44:16+00:00October 9th, 2025|Featured Posts| Share This Story, Choose Your Platform! FacebookXRedditLinkedInTumblrPinterestVkEmail